CAJ | 학술논문

目的评估睾丸切除或药物去势(醋酸戈舍瑞林)联合比卡鲁胺与单纯睾丸切除治疗晚期前列腺癌的疗效及安全性.方法筛选2003年1月至2012年10月80例晚期前列腺癌病人进行随访评估.其中睾丸切除联合比卡鲁胺治疗的35例为A组；药物去势(醋酸戈舍瑞林)联合比卡鲁胺25例为B组,单纯睾丸切除治疗的20例为C组.80例患者随访时间3 ～118个月,平均52个月.随访内容包括治疗后药物的副反应、全身情况、肝肾功能、扩散性疼痛、PSA水平、癌肿大小以及骨转移范围、2年生存率.评价上述指标在三组间的差异.结果随访期间,80例患者在药物的副反应、全身情况、肝肾功能、扩散性疼痛、PSA水平、癌肿大小以及骨转移范围等方面都得到观察研究,上述各研究内容在A组与B组间没有显著性差异、A组及B组与C组间有显著性差异,而三组的2年生存率分别为92％、93％、91％,没有显著性差异.结论标准内分泌治疗晚期前列腺癌是安全的,在病变的消退和稳定、扩散性疼痛的缓解、PSA水平的恢复和骨转移范围缩小等方面较单纯睾丸切除有较好的效果.
목적 평고고환절제혹약물거세(작산과사서림)연합비잡로알여단순고환절제치료만기전렬선암적료효급안전성.방법 사선2003년1월지2012년10월80례만기전렬선암병인진행수방평고.기중고환절제연합비잡로알치료적35례위A조；약물거세(작산과사서림)연합비잡로알25례위B조,단순고환절제치료적20례위C조.80례환자수방시간3 ～118개월,평균52개월.수방내용포괄치료후약물적부반응、전신정황、간신공능、확산성동통、PSA수평、암종대소이급골전이범위、2년생존솔.평개상술지표재삼조간적차이.결과 수방기간,80례환자재약물적부반응、전신정황、간신공능、확산성동통、PSA수평、암종대소이급골전이범위등방면도득도관찰연구,상술각연구내용재A조여B조간몰유현저성차이、A조급B조여C조간유현저성차이,이삼조적2년생존솔분별위92％、93％、91％,몰유현저성차이.결론 표준내분비치료만기전렬선암시안전적,재병변적소퇴화은정、확산성동통적완해、PSA수평적회복화골전이범위축소등방면교단순고환절제유교호적효과.
Objectives To investigate the clinical efficacy and safety of orchiectomy or medical castration (goserelin acetate) combined with bicalutamide or orchiectomy alone for treatment of advanced prostate cancer.Methods From January 2003 to Oct 2012,80 patients of advanced prostate cancer was divided into 3 groups.35 cases had been treated with orchiectomy combined with bicalutamide,which was group A.The other 25 cases had been treated with medical castration (goserelin acetate) combined with bicalutamide,which was group B.The group C,20 patients,was treated with orchiectomy alone.80 patients were followed up for 118 months to 3 months(an average of 52 months).Side effects,general conditions,liver and kidney function,diffused pain,level of PSA,tumor size and extent of bone metastasis,2-year survival rate were evaluated during follow up.The differences between the groups was analyzed statistically.Results During the follow-up,80 patients were studied on the drug's side effects,general conditions,liver and kidney function,diffuse pain,level of PSA,tumor size and extent of bone metastases,etc.There was no statistical significant difference between the group A and group B,However,there were statistical significant difference between group A and group C,group B and group C.Also,there were no statistical significant differences in the 2-year survival,which was 92％,93％ and 91％ in group A,group B and group C.Conclusions Standard endocrine treatment for the advanced prostate cancer is effective and safe.It has a good effect in the regression of lesions,relief the pain of metastasis,reduce the PSA level and bone metastases.Castration combined with bicalutamide is better than orchiectomy only.